MUMBAI, India, Jan. 23 -- Intellectual Property India has published a patent application (202511124318 A) filed by Gd Goenka University, Sohna, Haryana, on Dec. 9, 2025, for 'a novel in-situ nanoemulgel to reduce adverse drug reaction induced by antiglaucoma drugs.'
Inventor(s) include Monika Singh; Dr. Vikas Jhawat; and Ms. Monika Gulia.
The application for the patent was published on Jan. 23, under issue no. 04/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a novel in-situ nanoemulgel to reduce adverse drug reaction induced by antiglaucoma drugs. The present invention includes a bimatoprost, an oil phase, a hyaluronic acid, an emulsifier I, an emulsifier II, a water and a gelling agent. The bimatoprost having concentration of 0.03% w/v. The oil phase having concentration of 7.5% w/v. The oil phase is a source of an omega-3 fatty acid. The incorporation of omega-3 fatty acid and hyaluronic acid in the formulation of nanoemulgel is configured to attenuate or prevent ocular adverse reactions associated with anti-glaucoma medications. The emulsifier I having concentration of 11.25% w/v. The emulsifier II having concentration of 11.25% w/v. The water having concentration of 70% w/v. The gelling agent having concentration of 0.25% w/v. The gelling agent converts sol form into gel form when combined with tear fluid. A preservative free stable in-situ nanoemulgel is prepared to reduce ocular irritation and for better patient compliance."
Disclaimer: Curated by HT Syndication.
